Search Videos and More
Symposium
ESMO Congress 2026
Preview news releases and presentations by Dana-Farber Physician-Scientists at this year's ESMO Congress 2026 in Madrid, Spain, October 23 - 27, 2026.
Document
Treatment Guideline: Elinzanetant in Patients with a Breast Cancer and Vasomotor Symptoms
The Breast Oncology Center held meetings to discuss recommendations regarding the use of elinzanetant in patients with a history of breast cancer and vasomotor symptoms.
News
Novel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast Cancer
Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.
News
Dana-Farber Research News 10.01.2026
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from September 1 - 15.
Video
Brian Wolpin Celebrates FDA Approval of Daraxonrasib in Pancreatic Cancer as the Future of the Field
he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Course
Cannabis and Oncology Care: How to Guide Adults with Cancer
Learn evidence-based cannabis therapeutics for oncology patients — including clinical indications, risk assessment, and conversation frameworks-grounded in ASCO's 2024 clinical guideline for adults with cancer.
News
Dana-Farber Researchers Find Blood Test Could Guide Future Treatment in Ewing Sarcoma
Prospective national study validates circulating tumor DNA as a predictor of relapse risk and identifies low-, intermediate-, and high-risk patient groups
Podcast
Season 3, Episode 1: Advances in Endometrial Cancer Research
Cigall Kadoch had a hunch that the research in her lab might be relevant to endometrial cancer research. She had spent more than a decade studying the molecular machinery that unwinds DNA in the nucleus of a cell to make the right DNA instructions readable by the cell at the right time.
News
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see. New research from Dana-Farber Cancer Institute scientists reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells and suggests a therapeutic strategy as a countermeasure: Change what the cancer displays on its surface so the immune system can recognize the tumor.
News
Rare Inherited EGFR Mutation Linked to Dramatically Increased Lung Cancer Risk
A rare inherited mutation in the Epidermal Growth Factor Receptor (EGFR) gene is associated with a 25-fold increased risk of lung cancer, according to a study by investigators at Dana-Farber Cancer Institute and 23andMe Research Institute. The findings included de-identified, aggregated genetic data from more than 3.3 million 23andMe research-consented participants.
News
Dana-Farber’s Edward Chouchani, PhD, selected as a 2026 Blavatnik National Award finalist
Edward Chouchani, PhD, principal investigator of the Chouchani Lab at Dana-Farber Cancer Institute, was one of 18 scientists named as finalists for the 2026 Blavatnik National Awards for Young Scientists, a significant prize for early-career researchers.
Podcast Program
Unraveled